Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Top Cited Papers
- 27 May 2016
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 17 (7), 956-965
- https://doi.org/10.1016/s1470-2045(16)30066-3
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesisJournal of Translational Medicine, 2011
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Direct multiplexed measurement of gene expression with color-coded probe pairsNature Biotechnology, 2008
- Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based TherapyJournal of Clinical Oncology, 2007
- The chemoradiation paradigm in head and neck cancerNature Clinical Practice Oncology, 2007
- PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2European Journal of Immunology, 2002
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte ActivationThe Journal of Experimental Medicine, 2000